New hope for ALS patients: experimental drug aims to slow deadly disease
Disease control
Ongoing
This study is testing whether a new oral drug called Usnoflast can slow the progression of ALS (Lou Gehrig's disease). It involves 240 adults with early-stage ALS who will take either the drug or a placebo for 36 weeks, followed by an optional 16-week period where everyone gets t…
Phase: PHASE2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC